Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers

  • ID: 4403061
  • Report
  • Region: Global
  • 155 Pages
  • GBI Research
1 of 5
Global Revenue from the Respiratory Market is Forecast to Increase from $30.9 Billion in 2016 to $41.3 Billion in 2023, at a CAGR of 4.23%

FEATURED COMPANIES

  • Astellas
  • Astra Zeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Merck & Co.
  • Novartis
  • MORE

Summary

Respiratory disorders, which affect components of the respiratory system such as the lungs and airway, are a broad range of chronic diseases with a variety of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate the muscles surrounding the bronchial tubes to relax and open the airways.

Recently approved products in COPD include multiple LABA/LAMA fixed-dose combinations, some of which are forecast to generate over $1 billion by 2023, and include GlaxoSmithKline (GSK)’s triple-combination therapy (fluticasone furoate plus umeclidinium bromide plus vilanterol trifenatate). The approval of novel biologics in the asthma market, including interleukin (IL)-targeting Nucala (mepolizumab), marketed by GSK, is also forecast to have a strong commercial impact on the market. Notable drivers of growth in the cystic fibrosis (CF) market are the recently approved disease-modifying therapies Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor), both from Vertex.

Respiratory therapy area consists of indications that affect the lungs, bronchi, trachea, larynx, pharynx and nose in different ways, such as the scarring of lung tissue or the excessive production of mucus. Respiratory disease most commonly results in breathing difficulties, which can lead to disruptions in sleep, wheezing, anxiety and stress. In more severe cases shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders varies significantly across each indication and includes factors such as environment, occupation, genetic predisposition and aging.

In 2016, GSK was the leading company in terms of revenue generated from respiratory disorder products, accounting for 30.3% of the market, while Vertex had a small market share of 5.3%. However, the emergence of cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, which are considered disease-modifying therapies for CF, an indication which has traditionally only had symptomatic treatments, is set to have a substantial clinical and commercial impact. There are only two of these products on the market, Orkambi and Kalydeco, both of which were developed by Vertex.

The report "Global Respiratory Drugs Market to 2023 A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers" provides the following analysis:

  • Provides introduction to respiratory disorders, including disease epidemiology, symptoms, pathophysiology, co-morbidities and complications and prognosis. Methods of diagnosis are also provided. The chapter concludes with an analysis of the general treatment options.
  • Provides overview of the marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the respiratory disorders pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: leukemia, lymphoma and myeloma. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.
  • Presents forecast projections to 2023 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenues.
  • Analyzes trends in co-development and licensing deals, relating to respiratory disorder products. Some of the most prominent deals are discussed in detail.

Scope

  • Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%. What is driving this growth?
  • The leading companies in terms of market share are GSK, AstraZeneca and Boehringer Ingelheim. Which of these are forecast to experience the largest growth?
  • There have been many new approvals in the therapy area. Which drugs will achieve blockbuster status?
  • The market has been dominated by ICS/LABA therapies. What classes of drugs dominate the market and which will dominate over the forecast period?
  • There are 930 respiratory products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
  • Respiratory disorders clinical trials have an overall attrition rate of around 70%, what can companies do to maximize their chance of success?

Reasons to buy

  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Analyze the respiratory pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at respiratory product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify commercial opportunities in the respiratory deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas
  • Astra Zeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Merck & Co.
  • Novartis
  • MORE

1 Table of Contents

2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Diagnosis
2.3.1 Asthma
2.3.2 Chronic Obstructive Pulmonary Disease
2.3.3 Idiopathic Pulmonary Fibrosis
2.3.4 Cystic Fibrosis
2.4 Etiology and Pathophysiology
2.4.1 Asthma
2.4.2 Chronic Obstructive Pulmonary Disease
2.4.3 Idiopathic Pulmonary Fibrosis
2.4.4 Cystic Fibrosis
2.5 Epidemiology
2.5.1 Asthma
2.5.2 Chronic Obstructive Pulmonary Disease
2.5.3 Idiopathic Pulmonary Fibrosis
2.5.4 Cystic Fibrosis
2.6 Prognosis and Disease Staging
2.6.1 Asthma
2.6.2 Chronic Obstructive Pulmonary Disease
2.6.3 Idiopathic Pulmonary Fibrosis
2.6.4 Cystic Fibrosis
2.7 Treatment
2.7.1 Asthma
2.7.2 Chronic Obstructive Pulmonary Disease
2.7.3 Idiopathic Pulmonary Fibrosis
2.7.4 Cystic Fibrosis

3 Key Marketed Products
3.1 Overview
3.2 Advair - GSK
3.3 Symbicort - AstraZeneca/Astellas
3.4 Spiriva - Boehringer Ingelheim
3.5 Xolair - Roche/Novartis
3.6 Ventolin - GSK
3.7 Pulmicort - Astra Zeneca
3.8 Orkambi - Vertex
3.9 Relvar/Breo Ellipta - GSK
3.10 Singulair - Merck & Co.
3.11 Esbriet - Roche
3.12 Kalydeco - Vertex
3.13 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.5 Assessment of Key Pipeline Products
4.5.1 Ivacaftor and Tezacaftor - Vertex
4.5.2 (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) - GlaxoSmithKline/Innoviva
4.5.3 Dupixent - Regeneron Pharmaceuticals/Sanofi
4.5.4 Benralizumab - AstraZeneca/Medimmune
4.5.5 Tralokinumab - AstraZeneca
4.5.6 PT010 (Budesonide plus Formoterol Fumarate plus Glycopyrrolate) - AstraZeneca/Pearl Therapeutics
4.5.7 Conclusion
4.6 Conclusion

5 Multi-scenario Market Forecast to 2023
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 G Protein-Coupled Receptors
5.3.2 Immune/Inflammatory Mediators
5.3.3 Transcription Factors
5.3.4 Signal Transduction
5.3.5 CFTR Modulator

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 GlaxoSmithKline
6.1.2 Vertex
6.1.3 AstraZeneca
6.1.4 Roche
6.1.5 Boehringer Ingelheim
6.1.6 Novartis
6.1.7 Teva
6.1.8 Sumitomo Dainippon
6.1.9 Regeneron
6.1.10 Merck & Co.
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deal by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type and Molecular Target
7.1.4 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued Above $100m

8 Appendix
8.1 Bibliography
8.2 All Pipeline Drugs by Phase
8.2.1 Discovery
8.2.2 Preclinical
8.2.3 IND/CTA-Filed/Phase 0
8.2.4 Phase I
8.2.5 Phase II
8.2.6 Phase III
8.2.7 Pre-registration
8.3 Abbreviations
8.4 Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Market Size and Revenue Forecasts
8.4.4 Pipeline Analysis
8.4.5 Competitive Landscape

List of Tables
Table 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology, 2017
Table 2: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 0-4 Years of Age
Table 3: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 5-11 Years of Age
Table 4: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Youths of 12 Years or More and Adults
Table 5: Respiratory Disorders Therapeutics Market, Global, COPD Disease Severity, 2016
Table 6: Respiratory Disorders Therapeutics Market, Global, COPD Patient Risk Categories, 2016
Table 7: Respiratory Disorders Therapeutics Market, Global, IPF Severity Classification, 2016
Table 8: Respiratory Disorders Therapeutics Market, Global, CF Severity Classification, 2016
Table 9: Respiratory Disorders Therapeutics Market, Global, COPD Treatment Algorithm, 2016
Table 10: Respiratory Disorders Therapeutics Market, Global, CF Treatment Plan, 2016
Table 11: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Advair, 2017
Table 12: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Symbicort, 2017
Table 13: Respiratory Disorders Therapeutics Market
Table 14: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Xolair, 2017
Table 15: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Ventolin, 2017
Table 16: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Pulmicort, 2017
Table 17: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Orkambi, 2017
Table 18: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Relvar/Breo Ellipta, 2017
Table 19: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Singulair, 2017
Table 20: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Esbriet, 2017
Table 21: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Kalydeco, 2017
Table 22: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023
Table 23: Respiratory Disorders Therapeutics Market, Global, Usage of Generics Across Key Indications, 2017
Table 24: Respiratory Disorders Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2017
Table 25: Respiratory Disorders Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2017

List of Figures
Figure 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Asthma, 2016-2023
Figure 2: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for COPD, 2016-2023
Figure 3: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Idiopathic Pulmonary Fibrosis, 2016-2023
Figure 4: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Cystic Fibrosis, 2016-2023
Figure 5: Respiratory Disorders Therapeutics Market, Schematic Representation of Potential Clinical Courses of IPF
Figure 6: Respiratory Disorders Therapeutics Market, Progression of CF
Figure 7: Respiratory Disorders Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2017
Figure 8: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Advair ($bn), 2006-2023
Figure 9: Respiratory Disorders Therapeutics Market, Advair Market Share Within Asthma, Global, 2006-2023
Figure 10: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Symbicort ($bn), 2006-2023
Figure 11: Respiratory Disorders Therapeutics Market, Symbicort Market Share Within Asthma, Global, 2006-2023
Figure 12: Respiratory Disorders Therapeutic Market, Global, Annual Revenue for Spiriva ($bn), 2006-2023
Figure 13: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Xolair ($m), 2006-2023
Figure 14: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Ventolin ($bn), 2006-2023
Figure 15: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Pulmicort ($bn), 2006-2023
Figure 16: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Orkambi ($bn), 2015-2023
Figure 17: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Relvar/Breo Ellipta ($bn), 2013-2023
Figure 18: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Singulair ($bn), 2006-2023
Figure 19: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Esbriet ($m), 2008-2023
Figure 20: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Kalydeco ($m), 2012-2023
Figure 21: Respiratory Disorders Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
Figure 22: Respiratory Disorders Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017
Figure 23: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Stage of Development, 2017
Figure 24: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecule Type, 2017
Figure 25: Respiratory Disorders Therapeutics Market, Global, Pipeline by Molecular Targets and Stage of Development, 2017
Figure 26: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecular Targets, 2017
Figure 27: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
Figure 28: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017
Figure 29: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017
Figure 30: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017
Figure 31: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
Figure 32: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
Figure 33: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017
Figure 34: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
Figure 35: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development, 2006-2017
Figure 36: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication, 2006-2017
Figure 37: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type, 2006-2017
Figure 38: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target, 2006-2017
Figure 39: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development, 2006-2017
Figure 40: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication, 2006-2017
Figure 41: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type, 2006-2017
Figure 42: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target, 2006-2017
Figure 43: Respiratory Disorders Therapeutics Market, Global, Revenue for Ivacaftor/Tezacaftor ($bn), 2018-2023
Figure 44: Respiratory Disorders Therapeutics Market, Global, Revenue for (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) ($m), 2017-2023
Figure 45: Respiratory Disorders Therapeutics Market, Global, Revenue for Dupixent ($m), 2017-2023
Figure 46: Respiratory Disorders Therapeutics Market, Global, Revenue for Benralizumab ($m), 2017-2023
Figure 47: Respiratory Disorders Therapeutics Market, Global, Revenue for Tralokinumab ($m), 2017-2023
Figure 48: Respiratory Disorders Therapeutics Market, Global, Revenue for PT010 ($m), 2017-2023
Figure 49: Respiratory Disorders Therapeutics Market, Global, Market Size ($bn), 2016-2023
Figure 50: Respiratory Disorders Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016-2023
Figure 51: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for G Protein-Coupled Receptor Modulators ($bn), 2016-2023
Figure 52: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Immune/Inflammatory System Targets ($bn), 2016-2023
Figure 53: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Transcription Factor Therapies ($bn), 2016-2023
Figure 54: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Signal Transduction Modulators ($bn), 2016-2023
Figure 55: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for CFTR Modulators ($bn), 2016-2023
Figure 56: Respiratory Disorders Therapeutics Market, Global, Company Analysis Matrix, 2016-2023
Figure 57: Respiratory Disorders Therapeutics Market, Global, Cluster Graph by Growth and Market Share, 2016-2023
Figure 58: Respiratory Disorders Therapeutics Market, Global, Forecast Revenue by Company, 2016-2023
Figure 59: Respiratory Disorders Therapeutics Market, Global, Forecast Market Share by Company (%), 2016-2023
Figure 60: Respiratory Disorders Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
Figure 61: Respiratory Disorders Therapeutics Market, Global, Revenue by Product Type, 2016-2023
Figure 62: Respiratory Disorders Therapeutics Market, Global, GlaxoSmithKline Annual Revenue Forecast ($bn), 2016-2023
Figure 63: Respiratory Disorders Therapeutics Market, Global, Vertex Annual Revenue Forecast ($bn), 2016-2023
Figure 64: Respiratory Disorders Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2016-2023
Figure 65: Respiratory Disorders Therapeutics Market, Global, Roche Annual Revenue Forecast ($bn), 2016-2023
Figure 66: Respiratory Disorders Therapeutics Market, Global, Boehringer Ingelheim Annual Revenue Forecast ($bn), 2016-2023
Figure 67: Respiratory Disorders Therapeutics Market, Global, Novartis Annual Revenue Forecast ($m), 2016-2023
Figure 68: Respiratory Disorders Therapeutics Market, Global, Teva Annual Revenue Forecast ($bn), 2016-2023
Figure 69: Respiratory Disorders Therapeutics Market, Global, Sumitomo Dainippon Annual Revenue Forecast ($bn), 2016-2023
Figure 70: Respiratory Disorders Therapeutics Market, Global, Regeneron Annual Revenue Forecast ($bn), 2016-2023
Figure 71: Respiratory Disorders Therapeutics Market, Global, Merck & Co. Annual Revenue Forecast ($bn), 2016-2023
Figure 72: Respiratory Disorders Therapeutics Market, Global, Companies by Type, 2017
Figure 73: Respiratory Disorders Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Respiratory Specialization, 2017
Figure 74: Respiratory Disorders Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Disorders, 2016-2023
Figure 75: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006-2017
Figure 76: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Indication, 2006-2017
Figure 77: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Stage of Development, 2006-2017
Figure 78: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Molecule Type and Target, 2006-2017
Figure 79: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006-2017
Figure 80: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Indication, 2006-2017
Figure 81: Respiratory Disorders Therapeutics Market, Global, Co-development Deal Volume and Value by Stage of Development, 2006-2017
Figure 82: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Molecule Type and Target, 2006-2017
Figure 83: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Discovery, 2017
Figure 84: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Preclinical, 2017
Figure 85: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, IND/CTA-Filed/Phase 0, 2017
Figure 86: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase I, 2017
Figure 87: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase II, 2017
Figure 88: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase III, 2017
Figure 89: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Pre-registration, 2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astra Zeneca
  • Astellas
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Merck & Co.
  • Novartis
  • Regeneron
  • Roche
  • Sumitomo Dainippon
  • Teva
  • Vertex
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll